OrbiMed Capital GP VII LLC
CIK 1760648 · last filed 2025-12-18
OrbiMed Capital GP VII LLC is a corporate insider who has filed 31 SEC Form 4 insider transactions across 11 companies since 2020. The most recent filing shows the insider disposed of $11.4M of KROS on Dec 18, 2025. Across all open-market trades the lifetime net is +$225.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $232.4M across reported positions. The firm reports its address in New York, NY. 91 SEC filings were submitted jointly with ORBIMED ADVISORS LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$232.38M
11
31
$225.95M
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 45,057 | $11.08 | $499.2K | $18.01M | 2 | 2025-12-18 |
| PASG | 10%+ Owner | 313,980 | $5.00 | $1.57M | $17.76M | 13 | 2025-06-26 |
| MBX | Director | 3,205,930 | $59.02 | $189.21M | $6.06M | 1 | 2025-02-19 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $7.74M | 3 | 2024-02-14 |
| Damora Therapeutics, Inc. (GLTO) Delisted | Director | 36,571 | $28.69 | $1.05M | $52.66M | 2 | 2023-07-17 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 794,368 | $2.65 | $2.11M | $70.72M | 2 | 2023-05-02 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 762,400 | $52.95 | $40.37M | $5.00M | 1 | 2022-12-28 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 226,704 | $54.99 | $12.47M | $0 | 1 | 2022-01-28 |
| JANX | Director | 2,403,566 | $17.10 | $41.10M | -$22.50M | 1 | 2021-12-17 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 97,293 | $2.65 | $257.8K | $40.50M | 3 | 2021-09-02 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 633,100 | $14.59 | $9.24M | $30.00M | 1 | 2021-07-16 |
Recent Filings
31 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-18 | KROS | Disp (D) | −643,566 | -$11.42M | EDGAR |
| 2025-06-26 | PASG | Sell (S) | −1,167,314 | -$394.5K | EDGAR |
| 2025-04-24 | PASG | Sell (S) | −471,144 | -$157.5K | EDGAR |
| 2025-04-17 | PASG | Sell (S) | −298,108 | -$99.4K | EDGAR |
| 2025-02-19 | MBX | Buy (P) | +572,016 | $6.06M | EDGAR |
| 2025-01-14 | PASG | Sell (S) | −446,438 | -$284.4K | EDGAR |
| 2025-01-08 | PASG | Sell (S) | −294,048 | -$206.6K | EDGAR |
| 2024-12-26 | PASG | Sell (S) | −460,642 | -$276.4K | EDGAR |
| 2024-12-11 | PASG | Sell (S) | −124,552 | -$104.0K | EDGAR |
| 2024-11-05 | — | Mixed | +10,709,024 | $40.00M |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.